{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:37:45Z","timestamp":1778107065694,"version":"3.51.4"},"reference-count":42,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,12,18]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite its known cardiac and lung toxicities, the chemotherapy drug gemcitabine has only rarely been associated with pulmonary hypertension (PH), and the underlying mechanism remains unclear. The objective of the present study was to assess the association between gemcitabine and PH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified incident cases of precapillary PH confirmed by right heart catheterisation in patients treated with gemcitabine from the French PH Registry between January 2007 and December 2022. The aetiology, clinical, functional, radiological and haemodynamic characteristics of PH were reviewed at baseline and during follow-up. A pharmacovigilance disproportionality analysis was conducted using the World Health Organization (WHO) pharmacovigilance database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified nine cases of pulmonary arterial hypertension, either induced (in eight patients) or exacerbated (in one patient) by gemcitabine. Patients exhibited severe precapillary PH, with a median mean pulmonary arterial pressure of 40 (range 26\u201347) mmHg, a cardiac index of 2.4 (1.6\u20133.9) L\u00b7min<jats:sup>\u22121<\/jats:sup>\u00b7m<jats:sup>\u22122<\/jats:sup>and a pulmonary vascular resistance of 6.3 (3.1\u201312.6) Wood units. The median time from the initiation of gemcitabine to the onset of PH was 7 (4\u201350) months, with patients receiving a median of 16 (6\u201324) gemcitabine injections. Six patients showed clinical improvement upon discontinuation of gemcitabine. In the WHO pharmacovigilance database, we identified a significant signal with 109 cases reporting at least one adverse event related to PH with gemcitabine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both clinical cases and pharmacovigilance data substantiate a significant association between gemcitabine use and the onset or worsening of precapillary PH. The observed improvement following the discontinuation of treatment underscores the importance of PH screening in gemcitabine-exposed patients experiencing unexplained dyspnoea.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00654-2023","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:25:15Z","timestamp":1715876715000},"page":"00654-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics and outcomes of gemcitabine-associated pulmonary hypertension"],"prefix":"10.1183","volume":"10","author":[{"given":"Pierre","family":"Mouillot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Favrolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-8573","authenticated-orcid":false,"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1217-8442","authenticated-orcid":false,"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9borah","family":"Schenesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Jais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-5642","authenticated-orcid":false,"given":"Guillaume","family":"Beltramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolaine","family":"Georges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024101712142765000_10.3.00654-2023.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj941"},{"key":"2024101712142765000_10.3.00654-2023.2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11523-017-0486-5","article-title":"Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2017","journal-title":"Target Oncol"},{"key":"2024101712142765000_10.3.00654-2023.3","first-page":"S8-27\u2013S8-30","article-title":"Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer","volume":"24","author":"Shepherd","year":"1997","journal-title":"Semin Oncol"},{"key":"2024101712142765000_10.3.00654-2023.4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q"},{"key":"2024101712142765000_10.3.00654-2023.5","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016214032272"},{"key":"2024101712142765000_10.3.00654-2023.6","first-page":"189","article-title":"Pulmonary toxicity associated with gemcitabine","volume":"11","author":"Saif","year":"2010","journal-title":"J Pancreas"},{"key":"2024101712142765000_10.3.00654-2023.7","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802374262"},{"key":"2024101712142765000_10.3.00654-2023.8","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200202000-00021"},{"key":"2024101712142765000_10.3.00654-2023.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21808"},{"key":"2024101712142765000_10.3.00654-2023.10","unstructured":"Pneumotox online. The Drug-Induced Respiratory Disease Website. Date last accessed: 23 July 2022. www.pneumotox.com\/drug\/index\/"},{"key":"2024101712142765000_10.3.00654-2023.11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.revmed.2004.11.016","article-title":"Syndrome h\u00e9molytique et ur\u00e9mique secondaire \u00e0 la gemcitabine: \u00e0 propos de six observations et revue de la litt\u00e9rature","volume":"3","author":"Desram\u00e9","year":"2005","journal-title":"Rev Med Interne"},{"key":"2024101712142765000_10.3.00654-2023.12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009105"},{"key":"2024101712142765000_10.3.00654-2023.13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7819-11-167","article-title":"Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy","volume":"11","author":"Yakabe","year":"2013","journal-title":"World J Surg Oncol"},{"key":"2024101712142765000_10.3.00654-2023.14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh311"},{"key":"2024101712142765000_10.3.00654-2023.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1167-6"},{"key":"2024101712142765000_10.3.00654-2023.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018"},{"key":"2024101712142765000_10.3.00654-2023.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2024101712142765000_10.3.00654-2023.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.014207"},{"key":"2024101712142765000_10.3.00654-2023.19","first-page":"1","article-title":"A rare case of gemcitabine-induced pulmonary hypertension","volume":"5","author":"Shen","year":"2019","journal-title":"Pulm Res Respir Med"},{"key":"2024101712142765000_10.3.00654-2023.20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/1471-2407-13-542","article-title":"Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease","volume":"13","author":"Casadei Gardini","year":"2013","journal-title":"BMC Cancer"},{"key":"2024101712142765000_10.3.00654-2023.21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/CMO.S26537","article-title":"Gemcitabine-induced pulmonary toxicity: a case report of pulmonary veno-occlusive disease","volume":"9","author":"Turco","year":"2015","journal-title":"Clin Med Insights Oncol"},{"key":"2024101712142765000_10.3.00654-2023.22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-5002(00)00159-8","article-title":"Fatal pulmonary veno-occlusive disease possibly related to gemcitabine","volume":"31","author":"Vansteenkiste","year":"2001","journal-title":"Lung Cancer Amst Neth"},{"key":"2024101712142765000_10.3.00654-2023.23","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1111\/bcp.15436","article-title":"Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis","volume":"88","author":"Hlavaty","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024101712142765000_10.3.00654-2023.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01576-2021"},{"key":"2024101712142765000_10.3.00654-2023.25","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466"},{"key":"2024101712142765000_10.3.00654-2023.26","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"2024101712142765000_10.3.00654-2023.27","doi-asserted-by":"crossref","unstructured":"Fusaroli M , Raschi E , Gatti M , et al. Development of a network-based signal detection tool: the COVID-19 adversome in the FDA adverse event reporting system. Front Pharmacol 2021; 12: 740707.","DOI":"10.3389\/fphar.2021.740707"},{"key":"2024101712142765000_10.3.00654-2023.28","doi-asserted-by":"crossref","unstructured":"Humbert M , Kovacs G , Hoeper MM , et al. ESC\/ERS Scientific Document Group. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879.","DOI":"10.1183\/13993003.00879-2022"},{"key":"2024101712142765000_10.3.00654-2023.29","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0077-2016"},{"key":"2024101712142765000_10.3.00654-2023.30","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015141579"},{"key":"2024101712142765000_10.3.00654-2023.31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2003.12.004","article-title":"High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study","volume":"44","author":"Kouroussis","year":"2004","journal-title":"Lung Cancer Amst Neth"},{"key":"2024101712142765000_10.3.00654-2023.32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl507"},{"key":"2024101712142765000_10.3.00654-2023.33","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu441"},{"key":"2024101712142765000_10.3.00654-2023.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090608"},{"key":"2024101712142765000_10.3.00654-2023.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.10.021"},{"key":"2024101712142765000_10.3.00654-2023.36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.chest.2020.09.238","article-title":"Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by mitomycin C","volume":"159","author":"Certain","year":"2021","journal-title":"Chest"},{"key":"2024101712142765000_10.3.00654-2023.37","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0330-2020"},{"key":"2024101712142765000_10.3.00654-2023.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00026-2016"},{"key":"2024101712142765000_10.3.00654-2023.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.09.002"},{"key":"2024101712142765000_10.3.00654-2023.40","doi-asserted-by":"crossref","first-page":"e12053","DOI":"10.1002\/pul2.12053","article-title":"A second hit? Pulmonary arterial hypertension, BMPR2 mutation, and exposure to prescription amphetamines","volume":"12","author":"Jaliawala","year":"2022","journal-title":"Pulm Circ"},{"key":"2024101712142765000_10.3.00654-2023.41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00154210"},{"key":"2024101712142765000_10.3.00654-2023.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00654-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:37:29Z","timestamp":1740375449000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00654-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,20]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1183\/23120541.00654-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00654-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}